Harmand TJ, Bousbaine D, Chan A, et al. One-Pot Dual Labeling of IgG 1 and Preparation of C-to-C Fusion Proteins Through a Combination of Sortase A and Butelase 1. Bioconjug Chem. 2018;29(10):3245-3249. doi:10.1021/acs.bioconjchem.8b00563.
Koehler AN, Shamji AF, Schreiber SL. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. J Am Chem Soc. 2003;125(28):8420-1. doi:10.1021/ja0352698.
Yu H, Rosen MK, Shin TB, Seidel-Dugan C, Brugge JS, Schreiber SL. Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science. 1992;258(5088):1665-8.
Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018;173(6):1426-1438.e11. doi:10.1016/j.cell.2018.03.038.
Clemons PA, Gladstone BG, Seth A, Chao ED, Foley MA, Schreiber SL. Synthesis of calcineurin-resistant derivatives of FK506 and selection of compensatory receptors. Chem Biol. 2002;9(1):49-61.
Ferrer M, Kapoor TM, Strassmaier T, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol. 1999;6(10):953-60. doi:10.1038/13324.
Dumont JA, Liu T, Low SC, et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012;119(13):3024-30. doi:10.1182/blood-2011-08-367813.
Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A. 1999;96(8):4438-42.
Graef IA, Holsinger LJ, Diver S, Schreiber SL, Crabtree GR. Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70. EMBO J. 1997;16(18):5618-28. doi:10.1093/emboj/16.18.5618.
Stockwell BR, Schreiber SL. TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol. 1998;5(7):385-95.